PAKT

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 7, 2023
Cogent, Eurosport 1, C-peptide, Breast cancer, PAKT, HER2, Syndrome, Insulin, Half-life, Brain, Mouse, Cancer, PI3K, CNS, WT, Poster, NIH3T3, Patient, NCI, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today presented updated preclinical data from its potent, selective and brain penetrant ErbB2 inhibitor program along with initial preclinical data from its newly disclosed H1047R mutant-selective PI3Kα inhibitor discovery program at the 2023 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023 at the Henry B. González Convention Center in San Antonio, Texas. The posters can be found in the ‘Posters and Publications’ portion of the Cogent website.

Key Points: 
  • “In addition, we are pleased to present initial data on our effort to design a potent H1047R mutant-selective PI3Kα inhibitor.
  • The poster presented today shows that CGT4255 demonstrated low nM potency against ErbB2 wild-type and oncogenic ErbB2 mutations with 100-fold selectivity over wild-type-EGFR.
  • PI3Kα mutations are highly prevalent in many solid tumors and are present in 36% of all breast cancer patients.
  • Additional lead series analogs were also described, highlighting our more recent advances toward increasing selectivity and potency against H1047R mutants.

GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

Retrieved on: 
Tuesday, September 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, PAKT, Research, Professor, Rosacea, KA, Science, Frontiers of Medicine, Congress, AM, Population, IL-31, Thought, Patient, Genetics, RESEARCH, Atopic dermatitis, Sensitive, Woman, Prurigo nodularis, Adapalene, Partnership, Chairperson, Skin, Investment, Acne, Acquisition, Prurigo, Benzoyl peroxide, European Academy of Management, Nervous system, Cetaphil, Onychomycosis, Diagnosis, PM, Perkinsus marinus, Nail, Pharmaceutical industry, Cosmetics, Sculptra, Trifarotene, Methyl aminolevulinate, Ivermectin, Adapalene/benzoyl peroxide, Venereology, Galderma, Dermatology

Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.

Key Points: 
  • Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.
  • As the pure-play dermatology leader, Galdermas significant presence at EADV reaffirms its commitment to delivering a truly innovative, science-based portfolio of premium cutting-edge brands and services.
  • Two symposia and eight scientific posters will examine the disease burden, the role of IL-31 in these inflammatory skin conditions and treatments under development.
  • EADV congress to exchange information, share insights and
    GLOBAL HEAD OF RESEARCH & DEVELOPMENT, GALDERMA
    Below is a full list of activities taking place.

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination

Retrieved on: 
Friday, December 10, 2021
PI3K, Private Securities Litigation Reform Act, Compte rendu, Patient, Risk, U.S. Securities and Exchange Commission, Twitter, COVID-19, AKT, Nasdaq, Therapeutic index, Annual report, Breast cancer, Toxicity, Breast, FDA, GLOBE, PAKT, WT, Fulvestrant, Clinical trial, Safety, Therapy, Security (finance), PIK3CA, Cancer, Medical imaging, Vaccine, Pharmaceutical industry

The data presented in the poster help support the clinical development of RLY-2608 both in single agent and combination clinical trials for patients with PIK3CA (PI3K) mutant tumors, including PI3K-mutant, HR+/HER2- breast cancer.

Key Points: 
  • The data presented in the poster help support the clinical development of RLY-2608 both in single agent and combination clinical trials for patients with PIK3CA (PI3K) mutant tumors, including PI3K-mutant, HR+/HER2- breast cancer.
  • The data indicate RLY-2608 synergizes with fulvestrant and the CDK4/6 inhibitor abemaciclib in cell viability assays in PIK3CAmut/ER+/HER2- cell lines.
  • The triple combination of all three agents resulted in deep regressions across all models.
  • Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies.